A photo of the kit released by Patanjali on Twitter.
The medicine was launched at an event which was presided by Union Health Minister Harsh Vardhan and Transport Minister Nitin Gadkari. Haridwar-based Patanjali Ayurved on Friday said Coronil has now received certification from Ayush Ministry as per World Health Organization (WHO) certification scheme. The company claimed that it is the first evidence-based medicine to fight COVID-19. The medicine was launched here at an event which was presided by Union Health Minister Harsh Vardhan and Transport Minister Nitin Gadkari. Coronil has received the Certificate of Pharmaceutical Product (CoPP) from the Ayush section of Central Drugs Standard Control Organisation as per the WHO certification scheme, said Patanjali in a statement.
Ayurveda economy has seen up to 90 per cent growth post-COVID: Harsh Vardhan
SECTIONS
Last Updated: Feb 19, 2021, 04:31 PM IST
Share
Synopsis This (data) is of the pre-COVID era. Post-COVID, the economy of Ayurveda, which is Rs 30,000 crore with a growth of 15 to 20 per cent, has gone up to 50 to 90 per cent, he said.
Agencies
Harsh Vardhan, who himself is an MBBS and MS with specialisation in ENT and had practised as an ENT surgeon (as mentioned in his biography) said : Though I have practised modern medicine but after studying Ayurveda, I have come to conclusion that it is beneficial for all.
The medicine was launched here at an event that was presided by Union Health Minister Harsh Vardhan and Transport Minister Nitin Gadkari. "Coronil has received the Certificate of Pharmaceutical Product (CoPP) from the Ayush section of Central Drugs Standard Control Organisation as per the WHO certification scheme," said Patanjali in a statement.
Patanjali launches new corona medicine Coronil Baba Ramdev submits scientific research paper | Coronil: கொரோனா வைரசுக்கான புதிய மருந்தை அறிமுகப்படுத்தினார் பாபா ராம்தேவ் india.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from india.com Daily Mail and Mail on Sunday newspapers.